Quetiapine Efficacy in Bipolar Depression Study
Completed
- Conditions
- Bipolar Depression
- Registration Number
- NCT00523601
- Lead Sponsor
- AstraZeneca
- Brief Summary
To reassure the clinical study data on Seroquel antidepressant efficacy in patients who are diagnosed as bipolar depression
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
- The patient and the patient's legal representative (if any) must understand the nature of the study and must have given written consent
- Meet DSM-IV-TR criteria for bipolar depression at the time of baseline
Read More
Exclusion Criteria
- Since this programme intends to describe quetiapine use in routine clinical practice when prescribed as treatment of bipolar depression, there are no programme specific exclusion criteria, other than:
Or, any of the following is regarded as a criterion for exclusion from the programme:
- Serious or unstable, medical illness. Subjects with chronic illness may be included but must be stable and otherwise physically healthy on the basis of a physical examination, medical history
- Known intolerance for or lack of response to quetiapine, as judged by the investigator
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Research Site
🇰🇷Kyungki-do, Suwon-si, Korea, Republic of